Showing 8 posts of 8 posts found.


Ex-GSK exec named as Chief Medical Officer at Immatics Biotechnologies

June 10, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, appointment, immatics

Immatics Biotechnologies welcomed former GlaxoSmithKline executive Dr Cedrik Britten to the company as its new Chief Medical Officer (CMO) on …


Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies

August 29, 2019
Research and Development Cancer, Celgene, immatics, immunotherapy, pharma

Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …


Amgen and Immatics enter $1bn immuno-oncology partnership

January 9, 2017
Research and Development, Sales and Marketing Amgen, immatics, immunotherapy

Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over …


Immatics and MD Anderson launch new company to develop ACR therapies

August 27, 2015
Research and Development, Sales and Marketing Cancer, MD Anderson Cancer Center, immatics, keytruda

Immatics Biotechnologies and The University of Texas MD Anderson Cancer Center (MDACC) have together launched a new company focusing on …

Roche image

Roche signs $17 million immatics deal

November 15, 2013
Research and Development, Sales and Marketing Cancer, Roche, immatics, lung, prostate

Roche is to pay German biotech company immatics $17 million to collaborate on the search for vaccines in various cancers, …


immatics appoints Peter Chambré as chairman

November 12, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Peter Chambre, immatics

Biotech development firm immatics has announced the appointment of Peter Chambré as chairman of the Board. Chambré has had extensive …

immatics image

immatics’ vaccine increases survival in kidney cancer

July 30, 2012
Research and Development, Sales and Marketing IMA901, Vaccine, Yervoy, immatics, phase III

immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …


Immatics vaccine trials to be conducted with Cancer Research UK

February 16, 2010
Research and Development immatics, vaccines

Cancer Research Technology, the development and commercial arm of Cancer Research UK, has reached an agreement to collaborate with German-based …

Latest content